|
ACOSOG Z4099/ RTOG 1021: A Randomized Phase III Study of Sublobar Resection
(+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High
Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).
| Principal Investigator: |
Cliff Connery, MD |
| Time frame of study: |
Ongoing |
| Location of Study: |
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center |
| Contact: |
Continuum Cancer Research Program
(212) 844-6286 |
The purpose of this study is to compare the results of sublobar resection
(removal of a small portion of a lung) with or without brachytherapy (radioactive
seeds placed in the body) to stereotactic body radiation therapy (SBRT),
which is radiation given by a specialized x-ray machine that targets your
lung cancer. The study will compare the effects these treatments have
on you and your lung cancer to find out if SBRT is as effective as sublobar
resection. This study is being done because SBRT may have fewer side effects
than sublobar resection, but we do not know if SBRT is as effective at
preventing your cancer from returning or at prolonging your life. SBRT
is the current standard treatment for patients who are not candidates
for surgery.
• Male and female of at least 18 years old with biopsy-proven non-small
cell lung cancer (NSCLC)
• Tumor verified by a thoracic surgeon to be in a location that
will permit sublobar resection (surgical removal of a lobe of the lung)
• No evidence of distant metastases (spreading to the rest of the
body)
• No previous chemotherapy or surgical resection for lung cancer
Please call for more information.
|